Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party

Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party

Autologous haematopoietic stem cell transplantation (AHSCT) is an emerging therapeutic option for refractory Crohn’s disease (CD). The ASTIC trial of AHSCT failed to meet its stringent composite primary endpoint, but 1-year follow-up data demonstrate sustained efficacy. The real-world use and outcom...

Full description

Bibliographic Details
Main Authors: Brierley, C, Castilla-Llorente, C, Labopin, M, Badoglio, M, Rovira, M, Ricart, E, Dierickx, D, Vermeire, S, Hasselblatt, P, Finke, J, Onida, F, Cassinotti, A, Satsangi, J, Kazmi, M, Lopez-Sanroman, A, Farge, D, Travis, S, Hawkey, C, Snowden, J
Format: Conference item
Published: Oxford University Press 2018
Description
Summary:Autologous haematopoietic stem cell transplantation (AHSCT) is an emerging therapeutic option for refractory Crohn’s disease (CD). The ASTIC trial of AHSCT failed to meet its stringent composite primary endpoint, but 1-year follow-up data demonstrate sustained efficacy. The real-world use and outcomes of AHSCT for CD are unknown. Using the EBMT registry, we evaluated long-term outcomes for patients (pts) undergoing AHSCT for CD in Europe.

Similar Items